Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to 0.92.

  • Amylyx Pharmaceuticals' Equity Ratio rose 1695.19% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 1695.19%. This contributed to the annual value of 0.85 for FY2024, which is 158.61% up from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Equity Ratio of 0.92 as of Q3 2025, which was up 1695.19% from 0.86 recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Equity Ratio's 5-year high stood at 0.92 during Q1 2025, with a 5-year trough of 1.43 in Q4 2021.
  • Its 5-year average for Equity Ratio is 0.71, with a median of 0.85 in 2022.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Equity Ratio surged by 16079.05% in 2022 and then tumbled by 1272.96% in 2024.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Equity Ratio stood at 1.43 in 2021, then skyrocketed by 160.79% to 0.87 in 2022, then fell by 3.73% to 0.84 in 2023, then rose by 1.59% to 0.85 in 2024, then rose by 7.56% to 0.92 in 2025.
  • Its Equity Ratio was 0.92 in Q3 2025, compared to 0.86 in Q2 2025 and 0.92 in Q1 2025.